Israeli pharmaceutical company Can-Fite BioPharma Ltd. has announced that it has raised NIS 26.5 million ($7.2 million) in its secondary offering on the Tel Aviv stock exchange. The company says that it will direct the funds towards a phase II/III clinical trial of its psoriasis treatment.
Related posts
Israel Invests Millions To Help AI Comprehend Hebrew, Arabic
September 21, 2023
Cybersecurity Startup Cato Raises $238M With $3B Valuation
September 21, 2023
Israel, UK Ink Deal For Greater Innovation Collaboration
September 21, 2023
ALS Drug Receives Patent In Israel, Europe, Japan
September 20, 2023
Facebook comments